Comparison · NCT00344370-dc4bb219
Pitavastatin 4 mg vs Atorvastatin 40 mg: NCEP LDL-C Target Attainment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pitavastatin 4 mg vs Atorvastatin 40 mg: NCEP LDL-C Target Attainment. Trial comparisons, record NCT00344370-dc4bb219. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00344370-dc4bb219
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.78 | 0.705 | 0.841 | wilson | |
| Risk in group 2 | 0.775 | 0.665 | 0.856 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00549 | -0.106 | 0.131 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.864 | 1.17 | log | |
| Odds ratio, group 1 over group 2 | 1.03 | 0.521 | 2.05 | log | |
| Number needed to treat, for one more participant with the outcome on Pitavastatin 4 mg than on Atorvastatin 40 mg | 182 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pitavastatin 4 mg | Pitavastatin 4 mg once daily | 110 | 141 | OG000 |
| Group 2 | Atorvastatin 40 mg | Atorvastatin 40 mg once daily | 55 | 71 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- NCEP LDL-C Target Attainment
- Description
- Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at 44 weeks. According to NCEP criteria the target LDL-C is 100 mg/dL for all patients in this study.
- Time frame
- 44 weeks
- Population
- The efficacy population is defined as all patients who received at least one dose of study drug and who had at least one on-treatment lipid assessment
Source ClinicalTrials.gov
Trial
- Title
- Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
- NCT number
- NCT00344370
- Phases
- PHASE3
- Conditions
- Type II Diabetes Mellitus, Dyslipidemia
- Interventions
- Pitavastatin, Atorvastatin
- Lead sponsor
- Kowa Research Europe
- Results first posted
- 2010-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00344370?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00344370-dc4bb219